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Abstract
Introduction: Bone marrow-derived mesenchymal stem cells (BM-MSCs) for clinical use should not be grown in
media containing fetal bovine serum (FBS), because of serum-related concerns over biosafety and batch-to-batch
variability. Previously, we described the preparation and use of a cell-free native extracellular matrix (ECM) made by
bone marrow cells (BM-ECM) which preserves stem cell properties and enhances proliferation. Here, we compare
colony-forming ability and differentiation of MSCs cultured on BM-ECM with a commercially available matrix
(CELLstart™) and tissue culture plastic (TCP) under serum-free conditions.
Methods: Primary MSCs from freshly isolated bone marrow-derived mononuclear cells or passaged MSCs (P1) were
grown in serum-containing (SCM) or serum-free (SFM) media on BM-ECM, CELLstart™, or TCP substrates. Proliferation, cell
composition (phenotype), colony-forming unit replication, and bone morphogenetic protein-2 (BMP-2) responsiveness
were compared among cells maintained on the three substrates.
Results: Proliferation of primary BM-MSCs was significantly higher in SCM than SFM, irrespectively of culture substrate,
suggesting that the expansion of these cells requires SCM. In contrast, passaged cells cultured on BM-ECM or CELLstart™
in SFM proliferated to nearly the same extent as cells in SCM. However, morphologically, those on BM-ECM were smaller
and more aligned, slender, and long.
Cells grown for 7 days on BM-ECM in SFM were 20–40 % more positive for MSC surface markers than cells
cultured on CELLstart™. Cells cultured on TCP contained the smallest number of cells positive for MSC markers.
MSC colony-forming ability in SFM, as measured by CFU-fibroblasts, was increased 10-, 9-, and 2-fold when P1
cells were cultured on BM-ECM, CELLstart™, and TCP, respectively. Significantly, CFU-adipocyte and -osteoblast
replication of cells grown on BM-ECM was dramatically increased over those on CELLstart™ (2X) and TCP (4-7X).
BM-MSCs, cultured in SFM and treated with BMP-2, retained their differentiation capacity better on BM-ECM than
on either of the other two substrates.
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Conclusions: Our findings indicate that BM-ECM provides a unique microenvironment that supports the colony-forming
ability of MSCs in SFM and preserves their stem cell properties. The establishment of a robust culture system, combining
native tissue-specific ECM and SFM, provides an avenue for preparing significant numbers of potent MSCs for cell-based
therapies in patients.
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Introduction
Bone marrow-derived mesenchymal stem cells (BM-
MSCs) not only replicate to produce identical daughter
stem cells (self-renewal) but can differentiate into many
distinct cell types, including osteoblasts, adipocytes,
chondrocytes, and myocytes [1–4]. Throughout life, MSCs
are continually involved in tissue regeneration and may be
potentially useful as cell-based therapies for a number of
diseases such as graft-versus-host disease, myocardial in-
farction, and diabetes (http://clinicaltrials.gov/). However,
because of their relative scarcity in adult bone marrow
(approximately 0.001 %) [5, 6], MSCs must be expanded
in vitro to obtain sufficient numbers for basic research
studies or clinical applications. Typically, the growth of
MSCs requires a medium containing 10 % to 15 % fetal
bovine serum (FBS). For stem cell-based therapies, alter-
natives to FBS have been sought since there is significant
batch-to-batch variation from suppliers. More import-
antly, there are biosafety concerns, such as xenoim-
munization and the risk of disease transmission by
known or unknown pathogens (e.g., mycoplasma, viruses,
and prions) [7–9].
Efforts by others have focused on developing a defined
cell culture system consisting of a three-dimensional
(3D) matrix, composed of purified or recombinant matrix
proteins, combined with serum-free media (SFM) contain-
ing various growth factors for propagating MSCs in vitro
[10–13]. Although the results using this cell culture sys-
tem have shown promise when compared with culture on
ordinary tissue culture plastic (TCP), these purified or re-
combinant matrix proteins lack critical components found
in bone marrow extracellular matrix (BM-ECM). In vivo
MSCs are surrounded by a rich ECM, composed of
collagens, adhesion proteins, proteoglycans, and growth
factors, which forms a unique microenvironment known
as the “niche” [14, 15]. In this local microenvironment,
MSCs not only receive signals from the ECM but actively
remodel it by secreting various matrix components and
proteases and depositing storage depots of growth factors.
An accurate reconstruction of an authentic BM-ECM
from isolated components would be difficult because
of its intricate nature.
To preserve stem cell properties during culture, we
developed an experimental system which mimics the in
vivo microenvironment. In our approach, native ECM is
systematically produced by mouse or human bone mar-
row cells and then decellularized [16, 17]. This native
ECM is composed of at least 70 different components that
include collagens (types I and III), fibronectin, small
leucine-rich proteoglycans (biglycan and decorin), and
basement membrane constituents (perlecan and laminin).
Together, these matrix proteins play key roles in regulat-
ing cell adhesion, migration, proliferation, differentiation,
and survival [18–21]. Indeed, mouse and human BM-
MSCs, cultured on this cell-free BM-ECM, display en-
hanced attachment and proliferation while retaining
their stem cell properties [16, 17]. In addition, we found
that BM-MSCs maintained on BM-ECM displayed signifi-
cantly increased sensitivity to growth factors such as bone
morphogenetic protein-2 (BMP-2) [16]. Furthermore,
BM-MSCs expanded on BM-ECM in vitro and implanted
into immunocompromised mice generated five times
more bone and eight times more hematopoietic marrow
compared with MSCs expanded on plastic. The ability of
the ECM to promote retention of MSC properties is due,
at least in part, to sequestration of endogenously produced
growth factors that control MSC replication and differen-
tiation [16]. Recently, these findings have been independ-
ently supported by other groups [22–25].
In the present study, we hypothesize that BM-MSCs,
cultured on surfaces coated with BM-ECM, will display
significantly improved stem cell properties after expan-
sion compared with cells cultured on TCP or a commer-
cially available matrix (CELLstart™; Gibco Invitrogen,
Grand Island, NY, USA), critically evaluated and tested
by many research groups, and frequently used for growing
human stem cells [10–13, 26], under identical SFM condi-
tions. To test this hypothesis, we examined the capacity of
BM-MSCs, after growth in SFM on the various culture
substrates, for proliferation, MSC replication, differen-
tiation, and responsiveness to BMP-2.
Methods
Preparation of human BM-MSCs
Freshly isolated human bone marrow mononuclear cells,
containing BM-MSCs (primary cells) from 20- to 25-
year-old donors, were purchased from Lonza Group Ltd.
(Walkersville, MD, USA). Viability was more than 98 %
via trypan blue exclusion. These primary cells were seeded
into TCP plates (Sigma-Aldrich, St. Louis, MO, USA) at
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3 × 105 cells/cm2 in “expansion medium” containing
alpha-minimum essential medium (α-MEM) (Life Tech-
nologies, Grand Island, NY, USA), glutamine (2 mM),
penicillin (100 U/ml), streptomycin (100 μg/ml; Biofluids,
Rockville, MD, USA), and 15 % FBS (Becton Dickinson,
Franklin Lakes, NJ, USA) that had been pre-selected for
its growth enhancing activity. The cells were cultured for
2–3 weeks, reaching approximately 70–80 % confluence,
with half-volume media changes every 3–4 days. Non-
adherent cells were removed by washing with phosphate-
buffered saline (PBS). The adherent cells (passage 1; P1),
identified as MSCs based on high expression (>90 %) of
CD73, CD90, and CD105 and no expression of CD45,
were detached by using trypsin (0.02 % for 2 minutes at
37 °C), collected by centrifugation, and resuspended
in expansion media. At this point, cells were frozen for
future use, used in experiments examining cell behavior,
or used for the preparation of BM-ECM.
Preparation of cell-free BM-ECM
BM-ECM was prepared under aseptic conditions by using
procedures developed in our lab [16]. Briefly, BM-MSCs
(P1-P3 cells) were seeded onto TCP at 6 × 103 cells/cm2
and cultured in expansion medium for 15 days with media
changes every 3–4 days. During the last 8 days of culture,
ascorbic acid (50 μM) (Sigma-Aldrich) was added to the
media to stimulate matrix production. At harvest, the
BM-ECM was extensively washed with PBS and the cells
were removed by treating the matrix with 0.5 % Triton X-
100 containing 20 mM NH4OH in PBS for 5 minutes at
37 °C. The resulting BM-ECM was washed with PBS an
additional three times, followed by extensive washing with
sterile distilled water. After the final water wash, the ex-
cess fluid was removed, and the ECM was air-dried before
storing at 4 °C for up to 4 months. For use in cell culture,
the ECM was re-hydrated with PBS for 1 hour at 37 °C,
the PBS removed, and culture media added.
Surface characterization of cell-free BM-ECM and
commercial ECM (CELLstart™)
Surface mapping of BM-ECM and CELLstart™ (Gibco
Invitrogen) was performed by using a Veeco MultiMode
atomic force microscope (Bruker, Santa Barbara, CA,
USA) in tapping mode. Arithmetic mean roughness (Ra)
and average maximum height (Rz) were obtained by
measuring 15 samples of each cell culture substrate.
Proliferation of BM-MSCs maintained on TCP, cell-free
BM-ECM, or commercial ECM (CELLstart™) in serum-free
media
Both the proliferation of primary bone marrow cells and
passaged cells (P1) grown in SFM were examined. For
primary cell culture, freshly isolated human bone marrow
mononuclear cells from four different 20- to 25-year-old
donors (Lonza Group Ltd.) were seeded onto TCP, BM-
ECM, or TCP coated with CELLstart™ (Gibco Invitrogen)
prepared in accordance with the instructions of the manu-
facturer, in six-well plates at 5 × 105 cells/cm2. Cell cul-
tures were performed in parallel (n = 3) in two different
media: SFM, purchased from Gibco Invitrogen, was pre-
pared in accordance with the instructions of the manufac-
turer, while our regular “expansion medium” (see above)
was used for cultures in serum-containing media (SCM).
After 3 days in culture, media were removed and replaced
by fresh media to remove non-adherent cells. Once MSC
colonies appeared, half-volume media changes were per-
formed twice a week for 2 weeks. At harvest, non-adherent
cells were removed by washing with PBS. Owing to differ-
ences in attachment to the different substrates, two
methods of releasing the cells were required to optimize
recovery and maintain cell viability (>90 % using trypan
blue). Adherent cells on TCP were detached by using tryp-
sin, while cells on CELLstart™ and BM-ECM were de-
tached by using collagenase (type II; 400 U/ml) (Gibco
Invitrogen). Irrespectively of the enzyme used, all cells were
washed twice with PBS. Cell proliferation was assessed by
cell counting by using a hemocytometer and trypan blue
staining. Cell viability was consistently more than 90 %.
To examine the growth of passaged cells, early passage
(P1) BM-MSCs (6 × 103 cells/cm2) were seeded onto
TCP alone, BM-ECM, or CELLstart™ in six-well plates as
described above for primary cultures. Representative
cells were detached by using trypsin (cells on TCP) or
collagenase (type II) (cells on ECM-coated plates), and
counted after 4, 7, 10, 14, and 21 days of culture. Cell
surface markers were examined by using flow cytometry
(see “Flow cytometry” section below) to monitor changes
in phenotype over time.
In addition, cell morphology was evaluated after 4, 7, and
10 days in culture; at harvest, culture media were removed
and the cultures fixed overnight at 4 °C in 1 % paraformal-
dehyde. The next day the fixative was removed, 1 ml PBS
added, and the wells were sealed by using Parafilm (Sigma-
Aldrich). Subsequently, cells were viewed and photo-
graphed by using phase-contrast microscopy (Olympus
IX73; Olympus, Tokyo, Japan). The spreading shape of
cells, cultured on the various substrates for 3 days (before
they reached confluence), was compared by measuring cir-
cularity (in arbitrary units) using Olympus cellSens image
analysis software. Circularity (C) was calculated as a ratio
of cell area (in micrometers squared) to perimeter (in





Thus, the area of a cell with equal perimeter would
have an idealized circular shape and a circularity of “1”.
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Circularity values are reported as the mean ± standard
deviation (SD) of 60 randomly selected cells on a particu-
lar culture surface from three independent experiments.
Flow cytometry
Prior to seeding, baseline confirmation of BM-MSC
phenotype was confirmed via fluorescence-activated cell
sorting (FACS) analysis. For the present study, SSEA-4,
CD73, CD90, CD105, and CD146, known markers of
stem cells [27, 28], were analyzed to determine the
immunophenotypic profile of the cells before and after
culture on the various substrates. Single-cell suspensions
(1–2 × 106) were incubated for 30 minutes at 4 °C with
100-μl aliquots (1:10 dilution) of each primary mouse
antibody (SSEA-4, CD73, CD90, CD105, and CD146;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Non-specific isotype IgG was used as a negative control.
Antibody-labelled cells were washed twice with staining
buffer (PBS containing 5 % fetal calf serum and 0.01 %
sodium azide) and then incubated for 20 minutes at 4 °C
with 20 μg/ml secondary antibody (FITC-conjugated
goat anti-mouse IgG; Santa Cruz Biotechnology, Inc.).
Cells were then washed twice with staining buffer and
either analyzed immediately or fixed by using 400 μl/tube
of 1 % paraformaldehyde in PBS and stored at 4 °C until
analyzed. At least 10,000 events per sample were acquired
by using a Becton Dickinson FACStarplus flow cytometer
to determine the percentage of positively stained cells.
Colony-forming unit replication assay
MSC colony-forming ability was determined by using a
previously described replication assay [17]. Briefly, P1
bone marrow cells were seeded at 6 × 103 cells/cm2 onto
TCP, BM-ECM, or CELLstart™ and cultured in SFM for
7 days. At harvest, the cells were detached from the various
surfaces, counted, and re-seeded onto plastic plates for
determination of CFUs (see below). At the time of seeding
onto the three different substrates, an aliquot of the P1
cells was also seeded onto plastic plates for determination
of the initial numbers of CFUs as described below.
For CFU assay, cells before and after expansion on
the three substrates in SFM were plated into six-well
plates—100 cells per well for CFU-fibroblasts (CFU-F);
200 cells per well for CFU-adipocytes (CFU-AD) and
CFU-osteoblasts (CFU-OB)—in α-MEM containing 15 %
FBS. After 14 days in culture, CFU-F colonies were visual-
ized with crystal violet staining. To assess CFU-AD colony
formation, the cultures were maintained for an additional
10 days in adipogenic medium (DMEM containing 10 %
FBS, 0.5 mM IBMX, 10−6 M dexamethasone, 10 μM insu-
lin, and 200 μM indomethacin) [29] and then stained with
Oil Red O to visualize the colonies. To assess CFU-OB
colony formation, the cultures were maintained for an
additional 25 days in osteoblast differentiation medium:
expansion medium supplemented with 10−7 M dexa-
methasone (Sigma-Aldrich) and 10−4 M L-ascorbate-2-
phosphate (Wako Chemicals, Richmond, VA, USA). The
CFU-OB colonies were detected by von Kossa staining.
The number of CFUs formed, following 7 days of expan-
sion in SFM, was determined as previously described [17].
MSC replication was expressed as the fold change in
CFUs during the expansion: total number of CFUs ob-
tained after cell expansion divided by the initial number of
CFUs (before the expansion).
Determination of changes in osteoblast expression
following treatment with BMP-2
Early passage (P1) BM-MSCs (6 × 103 cells/cm2) were
seeded onto TCP, BM-ECM, or CELLstart™ in six-well
plates and cultured in SFM as described above for cell pro-
liferation. At day 7, the media were changed to α-MEM
containing 2 % pre-selected FBS and the cultures contin-
ued for an additional 24 hours. The cells were then treated
with recombinant human BMP-2 (60 ng/ml in PBS; Sigma-
Aldrich) or vehicle for 48 hours. The dose of rhBMP-2
selected was based on preliminary studies, in which con-
centrations ranging from 10 to 200 ng/ml were tested and
60 ng/ml was found to provide an optimal response.
Following BMP-2 treatment, total RNA was extracted
and reverse-transcribed by using a High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA).
Amplification of the cDNAs for alkaline phosphatase
(ALP), bone sialoprotein (BSP), and Runx2 was performed
by real-time PCR by using TaqMan Universal PCR Master
Mix and Assay-on-Demand primers (Applied Biosystems).
Amplification and detection were accomplished by using
an ABI 7500 Real-Time PCR System (Applied Biosys-
tems), and quantification of gene expression was obtained
by subtracting the GAPDH threshold cycle (Ct) value
from the Ct value of the gene of interest (ALP, BSP,
or Runx2). Quantification of transcript expression was
expressed as 2−ΔCt.
Statistical interpretation of data
For cell proliferation studies, each data point repre-
sented the mean ± standard deviation of three individual
cultures. The data were analyzed via multi-way analysis
of variance (ANOVA) following confirmation that all
assumptions for ANOVA were verified. Post hoc testing
was performed by using the Shapiro-Wilks normalcy
test. Log values of data points were analyzed, as nor-
malcy was not confirmed for raw data values. P values of
not more than 0.05 were considered significant. Cells
from four different donors (20–25 years old) were ob-
tained from Lonza Group Ltd. and assayed separately.
All results were obtained from at least three independ-
ent experiments, and each experimental treatment was
performed in triplicate.
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Results
Atomic force microscopy was used to assess the surface
characteristics of BM-ECM and CELLstart™. Visible dif-
ferences in surface topography between the two sub-
strates were easily discerned and quantitatively reflected
in significant differences in mean roughness and max-
imum height (Fig. 1). BM-ECM contained fibers with
regional directionality that formed “tracks” and had a
mean roughness of approximately 18 nm. In contrast,
CELLstart™ was more uniform and smooth and had a
mean roughness of approximately 1 nm.
When freshly isolated primary human bone marrow
mononuclear cells were cultured on TCP, BM-ECM, or
CELLstart™, the number of cells after 2 weeks was
significantly higher in SCM than SFM on all culture
surfaces (Fig. 2), suggesting that expansion of primary
human bone marrow cells requires SCM. Nevertheless,
the primary cells maintained on BM-ECM in SCM or
SFM always grew significantly faster than cells main-
tained on TCP or CELLstart™.
Next, we compared the proliferation of early passage
(P1) human bone marrow stromal cells on the three cul-
ture surfaces in SCM or SFM (Fig. 3). When cells were
cultured on either BM-ECM or CELLstart™ in SFM, pro-
liferation followed a temporal pattern similar to that ob-
served with SCM but was less robust. Cells cultured on
BM-ECM in SFM reached confluence earlier than those
on CELLstart™ (day 7 versus day 10). Except for day 10,
where the number of cells on CELLstart™ was signifi-
cantly higher, the number of cells in SFM cultures was
similar on both matrices. In multiple repeat experi-
ments, cells maintained for 7 days on BM-ECM in both
SCM and SFM were morphologically smaller and dis-
played more directional alignment when compared with
cells on TCP or CELLstart™ (Fig. 3, lower panels). Cell
circularity, after culture for 3 days in SFM, was signifi-
cantly reduced on BM-ECM versus TCP or CELLstart™
(0.06 ± 0.09, 0.24 ± 0.22, and 0.20 ± 0.23, respectively).
P1 cells that had been cultured on TCP, BM-ECM, and
CELLstart™ in SFM for 4 and 7 days were analyzed for
cell number and a panel of MSC surface markers
(SSEA-4, CD73, CD90, CD105, and CD146). Although
cells cultured for 4 days on BM-ECM showed a trend to-
ward greater numbers of MSCs, it never attained statis-
tical significance. In contrast, after 7 days in culture on
BM-ECM, the absolute number of cells and the percent
positive for MSC markers were significantly increased
over cultures on CELLstart™ (Table 1 and Fig. 4b). Dot
plots for cell scatter (Fig. 4a) revealed a different cell
distribution after culture on CELLstart™ versus BM-ECM
(small cells: approximately 30 % versus approximately
62 %; large cells: approximately 35 % versus approximately
Fig. 1 Topographical analysis of BM-ECM versus CELLstart™. a Atomic force microscope images highlight the different topographies of the two
culture surfaces, BM-ECM versus CELLstart™. The scan areas are 70 × 70 μm for BM-ECM and 20 × 20 μm for CELLstart™. Scale bar: the depth of
substrate shown by different colors. b Mean roughness and maximal (Max.) height of the two culture surfaces. Mean ± standard deviation was
calculated from 15 samples from both cell culture substrates. *P < 0.05, versus CELLstart™. BM-ECM bone marrow-derived extracellular matrix
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7 %, respectively). After both 4 and 7 days, cultures on
TCP contained the smallest number of cells and the low-
est percent positive for MSC markers by FACS analysis.
MSC colony-forming ability was assessed by measur-
ing the fold increase in CFU-F, CFU-AD, and CFU-OB
resulting from MSC replication during 7 days of culture
on TCP, BM-ECM, or CELLstart™ in SFM (Fig. 5). P1
cells were divided into aliquots for the determination of
CFUs present in the initial P1 population and for expan-
sion on TCP, BM-ECM, and CELLstart™, for the deter-
mination of replication as previously described [16].
After 7 days of culture on the various substrates in SFM,
the number of cells was obtained. The frequency of
CFUs in the cells expanded on the various substrates
was determined by plating the same number of cells on
TCP for the colony formation assay shown in Fig. 5a. By
combining the number of cells obtained from the
cultures on the various substrates after 7 days and the
frequency of CFUs, we determined that the number of
CFU-F was increased 10-, 9-, and 2-fold when P1 cells
were cultured on BM-ECM, CELLstart™, and TCP, re-
spectively (Fig. 5b). Furthermore, differentiation capacity
of the P1 cells was retained by culture on the various
substrates as demonstrated by the CFU-AD and CFU-
OB data (Fig. 5b). There was a significant increase in
replication, reflected in the increase in CFU-AD and OB,
after 7 days of culture on TCP, BM-ECM, or CELLstart™
that was above and beyond that observed for the CFU-F.
Specifically, CFU-AD and -OB were increased 16- and
56-fold, respectively, after culture on BM-ECM, which
was significantly higher than observed for CELLstart™
(8- and 24-fold, respectively) and TCP (4- and 8-fold,
respectively).
To determine whether MSCs retain their osteoblasto-
genic response to exogenous BMP-2 after culture on the
various substrates in SFM, P1 cells were grown on TCP,
BM-ECM, and CELLstart™ for 7 days and then treated
with BMP-2 (60 ng/ml) for 48 hours (Fig. 6). The ex-
pression of osteoblast markers—alkaline phosphatase
(ALP), bone sialoprotein (BSP), and Runx2—was mea-
sured by TaqMan PCR. P1 cells cultured on BM-ECM
and treated with BMP-2 demonstrate an increase in ALP
(168-fold), BSP (24-fold), and Runx2 (1.7-fold) expression
compared with untreated controls. In contrast, similarly
prepared cells maintained on CELLstart™ or TCP pro-
duced a 64- or 18-fold increase in ALP expression, a 7- or
5-fold increase in BSP expression, and a 1.2- or 0.9-fold
increase in Runx2 expression, respectively.
Discussion
Although the composition of CELLstart™ is proprietary,
we selected this culture substrate for comparison pur-
poses because (1) CELLstart™ has been well tested for
growing human MSCs [10–13, 26], (2) the same com-
pany that markets CELLstart™ also sells a compatible
serum-free medium, and (3) CELLstart™, which consists
of a mixture of human matrix proteins, is an ideal surface
to compare with our native ECM because we believe that
the native “undetached” ECM retains much of the unique
architecture critical for modulating MSC behavior.
In the present study, we compared the topographical
characteristics of BM-ECM and CELLstart™ and found
their structural organization and surface roughness to be
extremely different. One of the major advantages of BM-
ECM versus culture surfaces coated with purified ECM
proteins is the retention of the ECM’s unique architecture
and topographical features that are responsible for cell at-
tachment and migration [30]. In unpublished data, we
have observed that MSCs, maintained on BM-ECM, move
along the fibers and display directional migration but that
MSCs on TCP display random, non-directional behavior.
This indicates that culture on authentic ECM minimizes
contact inhibition and promotes cell proliferation.
Freshly isolated primary BM-MSCs cultured in SFM
proliferated to a much smaller degree than cells grown
in SCM, irrespective of the culture surface, during
14 days in culture. In addition, the number of MSCs re-
covered at the end of culture on BM-ECM was always
greater than that after culture on TCP or CELLstart™, ir-
respective of the culture media (Fig. 2). This was an
unexpected finding because an earlier report had
demonstrated similar patterns of primary cell growth
in SFM versus SCM as long as the cells were main-
tained on CELLstart™ [11]. In SCM, primary BM-MSCs
Fig. 2 Cell number of primary BM-MSCs after culture in SFM or SCM
for 14 days. Primary cultures of BM-MSCs were grown for 14 days on
TCP, BM-ECM, or CELLstart™ in SCM or SFM. At harvest, cell number
was determined by cell counting after staining with trypan blue. SCM
was superior to SFM in promoting cell proliferation, but the overall trend
observed with the three culture surfaces remained similar. *P< 0.05,
significantly different from BM-ECM and CELLstart™; †P< 0.05, significantly
different from BM-ECM. BM-ECM bone marrow-derived extracellular
matrix, BM-MSC bone marrow-derived mesenchymal stem cell, SCM
serum-containing media, SFM serum-free media, TCP tissue culture plastic
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expanded quickly and the number of cells found after
14 days in culture was related to culture substrate (BM-
ECM>CELLstart™ > TCP). Taken together, these results
suggest that SFM may not provide sufficient factors to
promote MSC proliferation in primary bone marrow
mononuclear cell culture. It is possible that other SFMs
reported in the literature are superior to the one used in
this study. Here, we selected Gibco Invitrogen SFM be-
cause it is made by the same supplier as CELLstart™ and
has been optimized for use with the CELLstart™ matrix.
Table 1 Percent positive cells obtained from cultures on the various substrates
SSEA-4 CD73 CD90 CD105 CD146
Time in culture Culture substrate
4 days TCP 29 ± 4 45 ± 4 45 ± 5 50 ± 4 24 ± 4
CELLstart™ 46 ± 5 50 ± 7 49 ± 4 47 ± 5 59 ± 7
BM-ECM 64 ± 6 67 ± 7 67 ± 5 65 ± 6 68 ± 7
7 days TCP N/A N/A N/A N/A N/A
CELLstart™ 45 ± 7 44 ± 8 61 ± 8 46 ± 9 65 ± 8
BM-ECM 81 ± 10 80 ± 6 81 ± 7 70 ± 6 83 ± 9
TCP tissue culture plastic, BM-ECM bone marrow-derived extracellular matrix, N/A not applicable
Early passage (P1) cultures of BM-MSCs were grown on TCP, BM-ECM, or CELLstart™ in SFM for 4 and 7 days. Phenotypic expression of MSC-associated markers
(SSEA-4, CD73, CD90, CD105, and CD146) was assessed by using flow cytometry. The data are the percent positive cells of the total cell population expressing each
marker. The experiment was performed in triplicate, and the mean ± standard deviation is shown. Each experiment was performed three times
Fig. 3 Cell number of early passage BM-MSCs after culture in SFM or SCM for 21 days. Early passage (P1) cultures of BM-MSCs were grown for up
to 21 days on TCP, BM-ECM, or CELLstart™ in SCM or SFM. At harvest, cell number was determined by cell counting after staining with trypan
blue. Morphology of the cells, after culture on the three different substrates for 7 days in SCM and SFM, is shown in phase-contrast micrographs
in the lower panels. Scale bar: 200 μm. BM-ECM bone marrow-derived extracellular matrix, BM-MSC bone marrow-derived mesenchymal stem cell,
SCM serum-containing media, SFM serum-free media, TCP tissue culture plastic
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This allowed us to focus on comparing the behavior of
the cells on BM-ECM versus CELLstart™ and minimize
differences in various SFM from different suppliers.
The typical constituents found in SCM are numerous
and include a wide range of macromolecules such as
serum proteins, attachment and spreading factors, growth
factors/hormones, and vitamins [31]. However, the key
components in SCM required to induce the proliferation
of primary MSCs remain to be elucidated and will need to
be optimized to complement the growth of MSCs during
culture on BM-ECM.
Passaged (P1 and beyond) cells exhibited very similar
growth trends in both SCM and SFM when cultured on
CELLstart™ or BM-ECM, but not TCP. This suggests
that when the cells are grown in SFM they become more
dependent on their culture substrate for maintenance of
proliferation, and this effect, compared with culture on
TCP, is significantly enhanced by culture on 3D matrices.
Although passaged cells cultured in SFM on BM-ECM
showed a statistically insignificant trend toward increased
proliferation compared with CELLstart™, the phenotype of
the cells after culture was quite different. Morphologically,
cells cultured on BM-ECM (versus CELLstart™) were
smaller, spindle-shaped, directionally oriented, and densely
packed and appeared more characteristic of viable stem
cells. FACS analysis of cells grown on the two 3D matrices
further confirmed these morphological observations. Cells
cultured on BM-ECM displayed greater expression of
MSC markers than cells cultured on CELLstart™, as well
as TCP, after 7 days (Fig. 4). These findings indicate that
the number of high-quality MSCs was increased when
they were maintained on BM-ECM, as compared with
TCP or CELLstart™, in a serum-free medium.
Fig. 4 Phenotypic expression of MSC surface markers after culture in
SFM for 4 and 7 days. Early passage (P1) cultures of BM-MSCs were
grown on TCP, BM-ECM, or CELLstart™ in SFM. Phenotypic expression of
MSC-associated markers (SSEA-4, CD73, CD90, CD105, and CD146) was
assessed by using flow cytometry. a Single-cell suspensions, derived from
7-day cultures on CELLstart™ or BM-ECM, were analyzed by fluorescence-
activated cell sorting. In the top panel, dot plots of the cell distribution
are shown. Relatively smaller cells are found in “range a” (CELLstart:
approximately 30 %; BM-ECM: 62 %), whereas relatively larger cells
are found in “range b” (CELLstart: approximately 35 %; BM-ECM:
7 %). In the lower panel, histograms represent the expression of the
indicated markers. Cells were stained with primary non-specific
antibody (isotype, IgG) as negative controls (gray peaks). b P1 cultures of
BM-MSCs were grown on the three culture surfaces for 4 (left panel) and
7 (right panel) days in SFM. The number of positive cells expressing each
marker was determined as a percentage of the total cell population (also
see Table 1). Mean ± standard deviation was calculated from three
independent experiments. *P< 0.05 versus CELLstart™. BM-ECM bone
marrow-derived extracellular matrix, BM-MSC bone marrow-derived
mesenchymal stem cell, CD, cluster of differentiation/determinants, FSC
forward scatter, MSC mesenchymal stem cell, P1 passage 1, SFM
serum-free media, SSC side scatter, SSEA-4 stage-specific embryonic
antigen-4, TCP tissue culture plastic
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To further assess cell quality after expansion on the
three different substrates in SFM, MSC colony-forming
capacity was measured by using a CFU replication assay
(Fig. 5). Consistent with the cell proliferation results, there
was no significant difference between cells pre-cultured on
BM-ECM versus CELLstart™ in terms of CFU-F replication.
However, only a very small proportion of the CFU-F gener-
ated cells, pre-cultured on TCP and CELLstart™, were able
to differentiate into CFU-OB. In contrast, almost 100 % of
the CFU-F, pre-cultured on BM-ECM, formed CFU-OB.
The results for CFU-AD were very similar to those ob-
served with CFU-OB. These data suggest that culture on
BM-ECM in SFM strongly preserves MSC differentiation
capacity when compared with culture on CELLstart™.
Previously, we reported that MSCs maintained on
BM-ECM in SCM displayed increased responsiveness to
Fig. 5 MSC self-renewal and retention of differentiation capacity after culture in SFM on TCP, BM-ECM, and CELLstart™. Early passage (P1) cultures
of BM-MSCs were cultured for 7 days on TCP, BM-ECM, or CELLstart™ in SFM. At harvest, the cells were detached, counted, and re-seeded onto
plastic plates for CFU assay (CFU-F, CFU-AD, and CFU-OB). Cells, before and after expansion, were plated into six-well plates in α-MEM containing
15 % FBS. After 14 days in culture, CFU-F colonies were stained with crystal violet and counted. Beginning on day 14, cultures for assay of CFU-AD were
changed to adipogenic media and cultured for an additional 10 days, and the colonies counted after staining with Oil Red O. Similarly, cultures for
assay of CFU-OB were changed to osteogenic media and cultured for an additional 25 days, and the colonies counted after Von Kossa
staining. a The appearance and frequency of CFU-F, CFU-AD, and CFU-OB assayed at the indicated seeding density before (initial) and
after 7 days of expansion on TCP, CELLstart™, and BM-ECM. b Over the course of 7 days in culture, MSC replication was represented by
the fold changes in the number of colonies after expansion on the various substrates. The mean ± standard deviation was calculated on the basis of
three independent experiments. *P < 0.05, versus CELLstart™; and ƗP < 0.05, versus TCP and initial. α-MEM alpha-minimum essential medium, BM-ECM
bone marrow-derived extracellular matrix, BM-MSC bone marrow-derived mesenchymal stem cell, CFU colony-forming unit, CFU-AD colony-forming
unit-adipocyte, CFU-F colony-forming unit-fibroblast, CFU-OB colony-forming unit-osteoblast, FBS fetal bovine serum, MSC mesenchymal stem cell,
P1 passage 1, SFM serum-free media, TCP tissue culture plastic
Rakian et al. Stem Cell Research & Therapy  (2015) 6:235 Page 9 of 11
BMP-2 [16]. Since growth factor responsiveness is
greatly affected by the local microenvironment of the
cells [32], we compared BMP-2 responsiveness of cells
maintained on BM-ECM, CELLstart™, and TCP in SFM.
Indeed, cells maintained on BM-ECM expressed remark-
ably higher levels of ALP and BSP in response to BMP-2
when compared with cells grown on CELLstart™ and
TCP (Fig. 6). In contrast to ALP and BSP, which are later
markers of osteoblast differentiation, Runx2 is a transcrip-
tion factor involved in early osteoblast differentiation [33].
The relatively low level of Runx2 expression in the present
study in response to BMP-2 may be due to the fact
that the cells were past the early stage of osteoblast
differentiation. These data strongly support the notion
that BM-ECM contains a unique architecture and
protein composition that specifically modulates the
presentation of growth factors to the cells as well as
their activation. It remains unclear how the ECM
controls cell response to growth factors. However,
earlier work has shown that many proteins in the
ECM bind various endogenous or exogenous growth
factors and serve as a reservoir for more efficiently
presenting them to their target cells [34–36].
Conclusions
In summary, our findings strongly indicate that native
BM-ECM provides a unique microenvironment that not
only improves the growth of MSCs in SFM but more
importantly preserves MSC quality in terms of replication,
differentiation, and BMP-2 responsiveness. The establish-
ment of a robust culture system consisting of native tissue-
specific ECM and defined SFM will allow us to prepare
significant numbers of MSCs, while retaining their stem
cell properties, for cell-based therapeutic applications.
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